Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661583 | 0.95 | HDAC2 (0.49) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3661824 | 0.91 | HDAC1 (0.52) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3663182 | 0.88 | HDAC2 (0.44) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3661228 | 0.88 | HDAC2 (0.47) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3663864 | 0.87 | HDAC2 (0.42) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3664613 | 0.84 | HDAC2 (0.43) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3665979 | 0.83 | KDM1A (0.42) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3663537 | 0.83 | HDAC2 (0.59) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3665163 | 0.82 | HDAC1 (0.49) | HDAC1HDAC2HPGDHDAC3KDM1A | |
| SCHEMBL3661503 | 0.82 | HDAC1 (0.61) | HDAC1HDAC2HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | claimed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC1 1/4885HDAC2 4/4885HPGD 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.